Investors aren't happy about the specialty pharmacy getting into the pharmacy benefit manager business.
The company was only in the black on a non-GAAP basis.
After positive phase 3 data, the biotech's first drug is ready to be submitted to regulators.
Spinraza sales continue to rise and the biotech has two drugs under review by regulators.
The specialty pharmacy is getting into the pharmacy benefit manager business.
But investors would have liked to have seen more.
The bigwigs came out to tout data to be presented at ASH.
Third-quarter earnings highlight bad news from the drugmaker.
A new CEO has the biotech's investors excited.
With lead program Forward I not scheduled to read out until 2019, investors have to be content with data from an earlier stage.
New phase 1/2 trial data show the biotech's drug candidate IMO-2125 is working.
The bioterrorism specialist posts a solid third quarter as it moves towards $1 billion in revenue in 2020.
The medical and life sciences conglomerate grows through cost savings.
Investors react to the huge run-up in price and the latest earnings report.
It was another lackluster quarter from the diabetes specialist.
Data in the biotech's earnings release has investors optimistic.
Potential label expansions are more important to the biotech's future than third-quarter sales of Cabometyx, but they still looked good.
There's more to come from the biodefense specialist after a solid third quarter.
Instrument placements gave birth to sales of high-margin consumables.
Data for the upcoming American Society of Hematology meeting failed to impress investors.